Overview

Application of Artemisia Pollen Specific Allergen Immunotherapy in Patients With Allergic Rhinitis in Autumn

Status:
Not yet recruiting

Trial end date:
2024-06-30

Target enrollment:

Participant gender:

Summary

Allergic rhinitis (AR) is a noninfectious inflammatory disease of the nasal mucosa mediated by immunoglobulin E (IgE) after exposure to allergens. Artemisia annua is one of the most important allergen that is responsible for seasonal AR in China during July and October. Allergen specific immunotherapy (AIT) is the only etiological treatment available for AR. The trial is a randomized, Open label, placebo-controlled, multicentred trial. A total of 150 subjects with allergic rhinitis caused by Artemisia pollen were recruited and randomized to the immunotherapy group and placebo group.

Phase:

Phase 4

Details

Lead Sponsor:

Beijing Tongren Hospital

Collaborators:

Beijing Shijitan Hospital, Capital Medical University
Peking University People's Hospital